You are here

  • Home
  • Archive
  • Volume 81, Issue 3
  • Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Article metrics

Article menu
Psoriatic arthritis
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2024

AbstractFullPdf
Nov 202112471225355
Dec 202116731671849
Jan 202214801489603
Feb 202212551248623
Mar 2022925924472
Apr 2022725716327
May 2022625624273
Jun 2022438427213
Jul 2022521522249
Aug 2022458470178
Sep 2022471478215
Oct 2022479461197
Nov 2022417412203
Dec 2022328319138
Jan 2023432420219
Feb 2023377375199
Mar 2023429428237
Apr 2023374363164
May 2023374358177
Jun 2023400374147
Jul 2023343332135
Aug 2023311290111
Sep 2023284269122
Oct 2023413396163
Nov 2023544520155
Dec 2023258255111
Jan 202414611979
Feb 2024366323128
Mar 2024446436202
Total16539162447244